Real Chemistry

Real Chemistry layers a venture investment arm and an in-house data science group on top of its marketing and communications practice. The venture unit takes equity in early-stage digital health companies, and the data science team builds proprietary analytics tools used for client engagements. This structure means client strategy can incorporate market signals from the portfolio companies and machine learning models that most standalone agencies do not have the resources to develop in-house.

Real Chemistry Ventures targets early-stage digital health, health-tech, and data-driven healthcare companies. The firm uses its industry relationships and analytics capabilities to identify technologies that address commercialization bottlenecks for biopharma. Known portfolio companies include Verana Health, which organizes real-world clinical data, and Woebot Health, which develops AI-based mental health chatbots.

Jim Weiss, the firm's founder and CEO, oversees strategic direction including the investment arm. The venture group operates as an integrated unit within the broader platform, blending investment decisions with the firm's analytics and client-facing expertise rather than functioning as an independent fund with a separate GP structure.

Real Chemistry is an asset manager in the broadest sense — it deploys capital through its venture arm into healthcare startups and manages a scaled services business that advises biopharma clients on commercialization. It is not a family office; the firm was founded by Jim Weiss and has grown through acquisitions and organic expansion, remaining privately held.

The firm is exclusively focused on healthcare, with deep specialization in biopharmaceutical commercialization, digital health, and health technology. Its client work centers on drug launch strategy, payer communications, and provider outreach, while the venture arm invests in tools and platforms that improve clinical data access, patient engagement, and health AI.